Litcius/Paper detail

Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies

Yuji Hosono, Brandon Sie, Iago Pinal‐Fernandez, Katherine Pak, Christopher A. Mecoli, María Casal-Domínguez, Blake M. Warner, Mariana J. Kaplan, Jemima Albayda, Sonye K. Danoff, Thomas E. Lloyd, Julie J. Paik, Eleni Tiniakou, Rohit Aggarwal, Chester V. Oddis, Siamak Moghadam‐Kia, Carmelo Carmona‐Rivera, José C. Milisenda, Josep M. Grau‐Junyent, Albert Selva-O’Callaghan, Lisa Christopher‐Stine, H. Benjamin Larman, Andrew L. Mammen

2022Annals of the Rheumatic Diseases38 citationsDOIOpen Access PDF

Topics & Concepts

AutoantibodyMedicineDermatomyositisPolymyositisRheumatoid factorImmunologyMyositisCancerCohortInternal medicineRheumatoid arthritisAntibodyInflammatory Myopathies and DermatomyositisSystemic Sclerosis and Related DiseasesSkin Diseases and Diabetes
Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies | Litcius